Abstract
Pharmacological investigations with tobramycin have been conducted in animals and in man.
In the experimental animal, tobramycin showed lower acute toxicity and lower nephrotoxicity than gentamicin. Moreover, the antibiotic did not cause any significant systemic effects and was rapidly absorbed in the blood and excreted in the urine.
The pharmacokinetic evaluation of tobramycin was undertaken in patients with varying degrees of reduced renal function.
The influence of peritoneal and extracorporeal dialysis on the removal of the antibiotic from the serum of patients with terminal renal failure was examined.
Possible tobramycin treatment schedules for patients with varying degrees of reduced renal function are briefly discussed.
Get full access to this article
View all access options for this article.
